

March 2, 2022



SCYNEXIS to Participate in Upcoming Scientific Conferences and Events

JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: [SCYX](#)), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conferences and one virtual investor panel in March. Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a live panel discussion on drug development in Women's Health. Event details can be found below:

Conferences:

- **International Society for the Study of Women's Sexual Health (ISSWSH)**
Date: March 3-6, 2022
Location: Dallas
[Event Page](#)
- **Council on Resident Education in Obstetrics and Gynecology (CREOG) & Association of Professors of Gynecology and Obstetrics (APGO) Annual Meeting**
Date: March 9-12, 2022
Location: Orlando
[Event Page](#)
- **Academy of Managed Care Pharmacy (AMCP)**
Date: March 29- April 1, 2022
Location: Chicago
[Event Page](#)

Virtual Investor Panel:

- **Maxim Group's Annual Growth Conference**
Panel: Women's Health Virtual Event
Date: March 28, 2022
Location: Virtual
Time: 3:00 p.m. ET
[Event Page](#)

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company's lead asset, ibrexafungerp (formerly known as SCY-078), as a

broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., [BREXAFEMME® \(ibrexafungerp tablets\)](#). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, late-stage clinical investigation of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Irina Koffler

Managing Director

LifeSci Advisors, LLC

646-970-4681

ikoffler@lifesciadvisors.com

Media Relations

Gloria Gasaatura

LifeSci Communications

646-970-4688

ggasaatura@lifescicomms.com



Source: Scynexis